MDCX Medicus Pharma receives positive FDA feedback and Central irb approval for optimized phase 2 teverelix® novel study in acute urinary re

MDCX Medicus Pharma receives positive FDA feedback and Central irb approval for optimized phase 2 teverelix® novel study in acute urinary retention Medicus Pharma - phase 2 study ant-2111-02 to evaluate teverelix dp in acute urinary retention